Clinical Trials Logo

Carcinoma clinical trials

View clinical trials related to Carcinoma.

Filter by:

NCT ID: NCT00045682 Completed - Clinical trials for Recurrent Ovarian Carcinoma

CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Start date: September 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of CT-2103 in treating patients who have recurrent or persistent ovarian epithelial cancer or primary peritoneal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00044564 Completed - Clinical trials for Carcinoma, Renal Cell

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Start date: December 2001
Phase: Phase 2
Study type: Interventional

In patients with renal cell cancer, most frequent methods of treatment include surgery, chemotherapy, hormonal therapy, and immunotherapy. Renal cell carcinoma is usually considered to be radioresistant and chemoresistant. In patients with metastatic disease, the options are limited. The taxanes are among the most commonly used class of chemotherapy agents in clinical oncology today but they are not effective in renal cancers; the development of Bay 59-8862 targets taxane-resistant tumors and the current protocol is designed to test the safety and efficacy of Bay 59-8862 in patients with advanced renal cell carcinoma.

NCT ID: NCT00044512 Completed - Clinical trials for Carcinoma, Hepatocellular

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Start date: August 2002
Phase: Phase 2
Study type: Interventional

Evaluate anti-cancer activity (e.g. proportion of patients with confirmed complete response or partial response) in patients with advanced, inoperable biopsy-proven hepatocellular carcinoma.

NCT ID: NCT00043407 Completed - Clinical trials for Carcinoma, Renal Cell

CPG 7909 in Patients Wih Stage IV Renal Cell Cancer

Start date: March 2002
Phase: Phase 1/Phase 2
Study type: Interventional

CPG 7909 given alone to patients with renal cell cancer after their nephrectomy. CPG 7909 is as a subcutaneous injection once per week for up to 24 weeks. Up to 40 patients will be included in the study.

NCT ID: NCT00043368 Completed - Melanoma Clinical Trials

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Start date: September 2002
Phase: Phase 2
Study type: Interventional

This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.

NCT ID: NCT00041652 Completed - Breast Cancer Clinical Trials

Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer

Start date: February 2000
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.

NCT ID: NCT00041093 Completed - Clinical trials for Recurrent Cervical Carcinoma

Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer

Start date: June 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of docetaxel in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00040599 Completed - Colorectal Cancer Clinical Trials

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Start date: January 2000
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to determine the safety of 90Y-hMN14 at different dose levels in the treatment of colorectal cancer.

NCT ID: NCT00039442 Completed - Clinical trials for Cervical Adenocarcinoma

Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer

Start date: April 29, 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of capecitabine in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00034879 Completed - Carcinoma Clinical Trials

Iressa Expanded Access Program (EAP)

Start date: August 2000
Phase: Phase 3
Study type: Interventional

A program for patients with non small cell lung cancer who may benefit from Iressa, but cannot enter another clinical trial due to them not being eligible, or for whom no trials are available.